WuXi Biologics: Spotlight On Property Disposal And Operating Metrics (Rating Upgrade)
WuXi Biologics is expected to deliver faster sales growth and higher margins this year. Click here to find out why I upgraded ...
WuXi Biologics: Buy Rating Supported by Strong Performance, Strategic Growth, and Increased Target Price
CMB International Securities analyst Jill Wu has maintained their bullish stance on WXIBF stock, giving a Buy rating on January 13.Stay Ahead ...
BioWorld18d
Wuxi Bio licenses trispecific T-cell engager to Candid for $925M
Wuxi Biologics Co. Ltd. is licensing a preclinical trispecific T-cell engager to Candid Therapeutics Inc. in a deal worth up to $925 million plus royalties.
Hosted on MSN20d
WuXi AppTec deal eases pressure from Congress on Penn and CHOP biotech
WuXi Biologics, a separate company, which makes therapies from living cells, has opened facilities in King of Prussia and Cranbury, N.J., in recent years. Altaris has invested in more than 40 life ...